In 2022, the Global Vaginitis Treatment Drugs Market Size is expected to be worth roughly US$ 3.01 billion. The market is predicted to develop at a 5.2% CAGR to reach US$ 4.52 billion by the end of 2030.
It has been shown that vaginal infections affect two-fifths of the world’s female population. If left untreated, vaginitis can lead to major difficulties and hazards such as miscarriage, premature births, and HIV-AIDS. Other illnesses, including as gonorrhoea, chlamydia, and papillomavirus, have been linked to potential problems. The fact that the majority of patients are asymptomatic makes finding vaginitis difficult. This makes it difficult to provide proper drugs.
Gain valuable insights into the factors driving the demand for Vaginitis Treatment Drugs to US$ 4.52 billion by 2030, Download Sample Report Now: https://www.futuremarketinsights.com/reports/sample/rep-gb-11790
As a result of the aforementioned changes, healthcare providers must prioritise research into the detection, diagnosis, and treatment of vaginitis infections. One of these ways is the development of appropriate pharmacological formulations, which has seen a significant increase in recent years. Treatment innovations are constantly being found, elevating the market in the forecast time.
“The Vaginitis Treatment Drugs market is slated to remain positive, with manufacturers concentrating on introducing non-antibiotic drugs as a long-term treatment solution in the wake of a high infection recurrence rate. Players are introducing single-dose and over-the-counter drugs which provide cost effective treatment,” infers an FMI analyst.
Key Takeaways from FMI’s Vaginitis Treatment Drugs Report:
- The market for vaginitis treatment pharmaceuticals is expected to reach US$ 3 billion by the end of 2020.
- Nitro Imidazole compounds are the highest income generators by drug category, accounting for 44% of total revenue over the projection period.
- Prescription medications lead the Vaginitis Treatment Drugs market by schedule, accounting for 75% of the market value.
- The return of bacterial vaginosis and complex vulvovaginal candidiasis (VVC) continues to be a major growth accelerator.
Vaginitis Treatment Drugs Market- Key Trends:
- The majority of vaginitis treatment medications are purchased from online pharmacies. The coronavirus pandemic has increased the use of online retail outlets to reduce the danger of virus exposure when visiting a physical pharmacy.
- Asymptomatic bacterial vaginosis affects at least half of all women. As a result, therapy is delayed, and difficulties continue to mount. This has prompted industry participants to speed developments that allow for the detection of asymptomatic instances.
Get Vaginitis Treatment Drugs Market Report At a Discounted Price: https://www.futuremarketinsights.com/request-discount/rep-gb-11790
Vaginitis Treatment Drugs Market- Region-wise Analysis:
- Europe’s Vaginitis Treatment Drugs market accounts for a quarter of the global Vaginitis Treatment Drugs market. Increased supply of vaginal tablets in pharmacies is stimulating market growth
- North America remains the most lucrative market, with the United States capturing the leading share. A higher rate of over the counter medicine availability is providing impetus for further growth
- South Africa and Brazil also represent credible opportunities as both are developing nations with a high incidence of vaginal infections
Vaginitis Treatment Drugs Market- Competitive Landscape:
The Vaginitis Treatment Drugs market is experiencing an influx of novel drugs. A number of clinical trials, drug development projects, establishment of distribution channels and e-commerce platforms are being witnessed. The market is highly consolidated, with over 25 players capturing a major chunk of the market.
The market players are incorporating nitro imidazole, tinidazole and metronidazole compounds in their formulations to manufacture vaginitis drugs. They are also concentration on strategic collaborations to introduce new drugs, such as the one between Basilea Pharmaceutica Ltd and Pfizer Inc in December 2017. The two giants collaborated to develop and commercialize Cresemba, an isavuconazole-based drug in the Asia-Pacific region.
Recently, Plush Care collaborated with Lupin Pharmaceuticals to facilitate bacterial vaginosis treatment through the former’s virtual care platform. This enables patients to virtually seek appointments with doctors, discuss the symptoms and get prescribed for lab testing.
Major Players in the Vaginitis Treatment Drugs Market:
- Pfizer Inc.
- Mylan NV
- Novartis AS
- Bayer AG
- Sanofi S.A.
- Lupin Pharmaceuticals, Inc.
- Dr Reddy’s Laboratories Ltd
- Cipla Ltd.
- Sun Pharmaceutical Industries Limited
Request Tailored Insights to Outperform in the Vaginitis Treatment Drugs Market: https://www.futuremarketinsights.com/customization-available/rep-gb-11790
Vaginitis Treatment Drugs Market Taxonomy:
Drug Type
- Nitro Imidazole Compounds
- Lincosamide Antibiotics
- Triazoles
- Imidazoles
Indication
- Bacterial Vaginitis
- Fungal Vaginitis (Yeast Infection)
- Trichomoniasis
Route of Administration
- Oral
- Cutaneous
- Vaginal
Schedule of Drug
- Prescription Drugs (Rx)
- Over-the-Counter Drugs (OTC)
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Mail Order Pharmacies
About Future Market Insights, Inc.
Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn | Twitter | Blogs